Cargando…
Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study
BACKGROUND: Dexamethasone intravitreal implant (DEX implant) is a biodegradable, sustained-release implant that releases dexamethasone for up to 6 months. We evaluated the efficacy and safety of DEX implant in the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naïv...
Autores principales: | Dugel, Pravin U., Capone, Antonio, Singer, Michael A., Dreyer, Richard F., Dodwell, David G., Roth, Daniel B., Shi, Rui, Walt, John G., Scott, Lanita C., Hollander, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558971/ https://www.ncbi.nlm.nih.gov/pubmed/26337664 http://dx.doi.org/10.1186/s12886-015-0106-z |
Ejemplares similares
-
Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study
por: Singer, Michael A, et al.
Publicado: (2015) -
Dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Dugel, Pravin U, et al.
Publicado: (2015) -
Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)
por: Blinder, Kevin J, et al.
Publicado: (2017) -
Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema
por: Castro-Navarro, Verónica, et al.
Publicado: (2019) -
Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes
por: Zarranz-Ventura, Javier, et al.
Publicado: (2020)